Literature DB >> 17603306

A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer.

Masahiro Hiraoka1, Satoshi Ishikura.   

Abstract

Stereotactic body radiation therapy (SBRT) is a new treatment modality. To confirm the safety and efficacy, the Radiation Therapy Study Group of the Japan Clinical Oncology Group (JCOG) has started a phase II study of SBRT for stage IA non-small cell lung cancer (JCOG 0403). This study is ongoing with a strict quality control and quality assurance program, and the results will indicate whether a future phase III trial comparing SBRT with surgery is warranted. In addition, international collaboration will be critical to establish the role of SBRT in the treatment of lung cancer.

Entities:  

Mesh：

Year:  2007        PMID： 17603306     DOI： 10.1097/JTO.0b013e318074de1b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  9 in total

Review 1.  Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors.

Authors:  Carmen Rubio; Rosa Morera; Ovidio Hernando; Thomas Leroy; S Eric Lartigau
Journal:  Rep Pract Oncol Radiother       Date:  2013-11-01

2.  Stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Ben J Slotman
Journal:  J Radiosurg SBRT       Date:  2011

Review 3.  Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.

Authors:  Tejan P Diwanji; Pranshu Mohindra; Melissa Vyfhuis; James W Snider; Chaitanya Kalavagunta; Sina Mossahebi; Jen Yu; Steven Feigenberg; Shahed N Badiyan
Journal:  Transl Lung Cancer Res       Date:  2017-04

4.  Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms.

Authors:  Wataru Takahashi; Hideomi Yamashita; Naoya Saotome; Yoshio Iwai; Akira Sakumi; Akihiro Haga; Keiichi Nakagawa
Journal:  Radiat Oncol       Date:  2012-02-09       Impact factor: 3.481

5.  Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy.

Authors:  Kotoha Tatekawa; Hiromitsu Iwata; Takatsune Kawaguchi; Satoshi Ishikura; Fumiya Baba; Shinya Otsuka; Akifumi Miyakawa; Maho Iwana; Yuta Shibamoto
Journal:  Radiat Oncol       Date:  2014-01-07       Impact factor: 3.481

6.  Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer: Japan Clinical Oncology Group trial (JCOG0702).

Authors:  Teiji Nishio; Hiroki Shirato; Masayori Ishikawa; Yuki Miyabe; Satoshi Kito; Yuichirou Narita; Rikiya Onimaru; Satoshi Ishikura; Yoshinori Ito; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2014-01-01       Impact factor: 2.724

7.  Stereotactic body radiotherapy for small lung tumors in the University of Tokyo Hospital.

Authors:  Hideomi Yamashita; Wataru Takahashi; Akihiro Haga; Satoshi Kida; Naoya Saotome; Keiichi Nakagawa
Journal:  Biomed Res Int       Date:  2014-07-07       Impact factor: 3.411

8.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.

Authors:  Coen W Hurkmans; Johan P Cuijpers; Frank J Lagerwaard; Joachim Widder; Uulke A van der Heide; Danny Schuring; Suresh Senan
Journal:  Radiat Oncol       Date:  2009-01-12       Impact factor: 3.481

9.  The impact of emphysema on dosimetric parameters for stereotactic body radiotherapy of the lung.

Authors:  Satoru Ochiai; Yoshihito Nomoto; Yasufumi Yamashita; Tomoki Inoue; Shuuichi Murashima; Daisuke Hasegawa; Yoshie Kurita; Yui Watanabe; Yutaka Toyomasu; Tomoko Kawamura; Akinori Takada; Shigeki Kobayashi; Hajime Sakuma
Journal:  J Radiat Res       Date:  2016-07-05       Impact factor: 2.724
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.